Technical Analysis for BIIB - Biogen Idec Inc.

Grade Last Price % Change Price Change
F 219.40 0.04% 0.09
BIIB closed up 0.04 percent on Monday, March 18, 2024, on 1.16 times normal volume. The stock exhibited some range contraction during this trading session as price made an NR7 -- narrowest range of the last seven sessions.
6 Watchers
Watchlist Portfolio

Trend Table & Recent EOD Trading Signals

ADX Long Term Intermediate Term Short Term
Strong Down Down Down

Date Alert Name Type % Chg
NR7 Range Contraction 0.00%
Inside Day Range Contraction 0.00%
20 DMA Resistance Bearish 0.04%
Fell Below 20 DMA Bearish -0.10%
180 Bearish Setup Bearish Swing Setup -0.10%
Gapped Down Weakness -0.10%
Crossed Above 20 DMA Bullish -4.64%
Up 3 Days in a Row Strength -4.64%
Up 4 Days in a Row Strength -4.64%
20 DMA Resistance Bearish -1.72%

   Recent Intraday Alerts

Alert Time
Possible NR7 about 17 hours ago
Possible Inside Day about 17 hours ago
60 Minute Opening Range Breakdown 4 days ago
Down 1% 4 days ago
2x Volume Pace 4 days ago

Free Daily (Stock) Chart Reading

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.

Profile

Biogen Idec Inc. Description

Biogen Idec Inc. discovers, develops, manufactures, and markets therapies for the treatment of neurodegenerative diseases, hemophilia, and autoimmune disorders in the United States and internationally. Its marketed products include AVONEX for the treatment of relapsing multiple sclerosis (MS); TYSABRI to treat relapsing MS; RITUXAN for treating relapsed or refractory, CD20-positive, and B-cell Non-Hodgkin's lymphoma (NHL); FUMADERM for the treatment of severe plaque psoriasis in adult patients; and FAMPYRA, an oral compound for the improvement of walking in adult patients with MS with walking disability. The company's products that completed Phase III clinical trials comprise TECFIDERA (BG-12) for MS; Peginterferon beta-1a to prolong the effects and reduce the dosing frequency of interferon beta-1a; and long-lasting Factor VIII and IX product candidates for the treatment of hemophilia. Its products under Phase III clinical trials consist of Daclizumab, a monoclonal antibody in relapsing MS; TYSABRI for secondary progressive MS; and GA101, a monoclonal antibody for chronic lymphocytic leukemia and NHL. The company's Phase II clinical trial products include Anti-LINGO for optic neuritis; STX-100 for idiopathic pulmonary fibrosis; and ANTI-TWAEK for lupus nephritis. The company's Phase I clinical trial products comprise Anti-LINGO for MS; BIIB037 for Alzheimer's disease; Neublastin for neuropathic pain; and Anti-CD40 Ligand for general lupus, as well as Phase 1b/2a clinical trial product includes ISIS-SMNRx for spinal muscular atrophy. It has collaboration agreements with Genentech, Inc.; Elan Pharma International, Ltd; Acorda Therapeutics, Inc.; Portola Pharmaceuticals, Inc.; and Swedish Orphan Biovitrum AB. The company was formerly known as IDEC Pharmaceuticals Corporation and changed its name to Biogen Idec Inc. in November 2003. Biogen Idec Inc. was founded in 1985 and is headquartered in Weston, Massachusetts.


Classification

Sector: Healthcare
Industry: Drug Manufacturers - Major
Keywords: S&P 500 Medicine Biotechnology Nasdaq 100 Immunology Pain Disability Monoclonal Antibodies Monoclonal Antibody Alzheimer's Disease Lymphoma Psoriasis Neurodegenerative Diseases Multiple Sclerosis Specialty Drugs Degenerative Disease Idiopathic Pulmonary Fibrosis Pulmonary Fibrosis Autoimmune Disorders Immune Disorders Lupus Chronic Lymphocytic Leukemia Lymphocytic Leukemia Progressive Clinical Trial Product Neuropathic Pain Hemophilia Interferon Immunosuppressants Spinal Muscular Atrophy Treatment Of Hemophilia Treatment Of Neurodegenerative Diseases Cd20 Lupus Nephritis Clinical Trial Products Nephritis Plaque Psoriasis Portola Pharmaceuticals Severe Plaque Psoriasis

Is BIIB a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength

Indicators

Indicator Value
52 Week High 319.76
52 Week Low 215.35
Average Volume 1,155,328
200-Day Moving Average 256.19
50-Day Moving Average 236.57
20-Day Moving Average 221.13
10-Day Moving Average 220.78
Average True Range 5.58
RSI (14) 41.52
ADX 30.35
+DI 16.24
-DI 25.28
Chandelier Exit (Long, 3 ATRs) 220.26
Chandelier Exit (Short, 3 ATRs) 232.09
Upper Bollinger Bands 227.06
Lower Bollinger Band 215.21
Percent B (%b) 0.35
BandWidth 5.36
MACD Line -4.20
MACD Signal Line -5.11
MACD Histogram 0.9075
Fundamentals Value
Market Cap 31.79 Billion
Num Shares 145 Million
EPS 10.05
Price-to-Earnings (P/E) Ratio 21.83
Price-to-Sales 3.49
Price-to-Book 2.41
PEG Ratio 6.24
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 223.78
Resistance 3 (R3) 223.68 222.12 223.05
Resistance 2 (R2) 222.12 221.00 222.17 222.81
Resistance 1 (R1) 220.76 220.32 219.98 220.86 222.56
Pivot Point 219.20 219.20 218.81 219.25 219.20
Support 1 (S1) 217.84 218.08 217.06 217.94 216.24
Support 2 (S2) 216.28 217.40 216.33 215.99
Support 3 (S3) 214.92 216.28 215.75
Support 4 (S4) 215.02